Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry

Mirjam Crul(Amsterdam University Medical Centers), Jos H. Beijnen(The Netherlands Cancer Institute), Jan H.M. Schellens(Utrecht University), H.J.G.D. van den Bongard(Slotervaartziekenhuis), Matthijs M. Tibben(Slotervaartziekenhuis), Olaf van Tellingen(Dutch Cancer Society), Gianni Sava(Italian Society of Physiotherapy)
Fresenius Journal of Analytical Chemistry
March 2, 2001
10.1007/s002160000662
Cited by 19

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884